2130. Safety and Pharmacokinetics of SPR206 in Subjects with Varying Degrees of Renal Impairment

por Bruss, Jon, Bader, Justin C, Hamed, Kamal
Publicado 2023

Traditional PK-PD Indices for Efficacy – Can We Do Better?

por Lakota, Elizabeth A, Bader, Justin C, Bhavnani, Sujata M, Andes, David R, Ambrose, Paul G
Publicado 2017

Time for Precision: A World Without Susceptibility Breakpoints

por Bader, Justin C, Lakota, Elizabeth A, Andes, David R, Rubino, Christopher M, Ambrose, Paul G, Bhavnani, Sujata M
Publicado 2018

1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against S. aureus (SA) and S....

por Lepak, Alexander J, Zhao, Miao, Liu, Qingmei, Wang, Ping, Wang, Yanli, Bader, Justin C, Ambrose, Paul G, Andes, David R
Publicado 2018

1340. Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data

por Trang, Michael, Bader, Justin C, Ople, Eric A, Kramer, William G, Hodges, Michael R, Bhavnani, Sujata M, Rubino, Christopher M
Publicado 2018

At the Crossroads of Stewardship and Technology: Impact of Pharmacokinetic-Pharmacodynamic (PK-PD) Integrated Electronic Decision Support Software (EDSS) on the Treatment of Patien...

por Bader, Justin C, Bulik, Catharine C, Bhavnani, Sujata M, Rubino, Christopher M, Sweeney, Kim L, Ambrose, Paul G, Owens, Robert C
Publicado 2017

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

por Bader, Justin C., Lakota, Elizabeth A., Flanagan, Shawn, Ong, Voon, Sandison, Taylor, Rubino, Christopher M., Bhavnani, Sujata M., Ambrose, Paul G.
Publicado 2018

Getting it Right the First Time: Relating Pharmacokinetic-Pharmacodynamic Target Attainment and Patient Outcomes

por Bulik, Catharine C, Bader, Justin C, Lakota, Elizabeth A, Bhavnani, Sujata M, Rubino, Christopher M, Sweeney, Kim L, Ambrose, Paul G, Owens, Robert C
Publicado 2017

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial...

por Bhavnani, Sujata M, Zhang, Li, Hammel, Jeffrey P, Rubino, Christopher M, Bader, Justin C, Sader, Helio S, Gelone, Steven P, Wicha, Wolfgang W, Ambrose, Paul G
Publicado 2019

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters

por Lakota, Elizabeth A., Bader, Justin C., Ong, Voon, Bartizal, Ken, Miesel, Lynn, Andes, David R., Bhavnani, Sujata M., Rubino, Christopher M., Ambrose, Paul G., Lepak, Alexander J.
Publicado 2017

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising...

por Bhavnani, Sujata M., Hammel, Jeffrey P., Lakota, Elizabeth A., Trang, Michael, Bader, Justin C., Bulik, Catharine C., VanScoy, Brian D., Rubino, Christopher M., Huband, Michael D., Friedrich, Lawrence, Steenbergen, Judith N., Ambrose, Paul G.
Publicado 2023